Filing Flows › Health Care › vTv Therapeutics (VTVT)
vTv Therapeutics (VTVT) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 13, 2026 · vTv Therapeutics (VTVT) Q1 2026 earnings results →
Q1 2026 66¢ of every $1 of revenue kept as net profit · operating margin 63.1%
vTv Therapeutics made $36.8M in Q1 2026. Operating margin 63.1%, net earnings $24.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $36.8M in Q1 2026.
Operating profit was $23.3M, a 63.1% margin. Net earnings were $24.1M. The effective tax rate was 0.0%.
Operating cash flow was $9.2M, 38% of net earnings. Non-cash charges added back $1K of depreciation and $1.4M of share-based compensation. Working capital and other items used $16.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 13, 2026 | $36.8M | — | 63.1% | $24.1M | $9.2M |
| Q4 2024 | 10-K | Mar 20, 2025 | $17K | — | n/m | −$4.4M | −$4.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About vTv Therapeutics
We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399) , is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The Cadisegliatin as Adjunctive Therapy to Insulin in Participants with Type 1 Diabetes ("CATT1") Phase 3 clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the effect of cadisegliatin on hypoglycemia outcomes in patients with T1D.
In its own words, from its 10-K, filed Mar 10, 2026.
vTv Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: 63.1% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VTVT vTv Therapeutics | Q1 2026 | $36.8M | — | 63.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: vTv Therapeutics 10-Q on SEC EDGAR · CIK 1641489 · Pharmaceutical Preparations
13F: who owns VTVT and who is buying
More on VTVT
History
Every quarter: Q1 2026 results · Q4 2024 results